AU2019422095A1 - ESTABLISHMENT METHOD OF CELL LINE FOR PREPARING ANTI-EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) FULLY-HUMANIZED MONOCLONAL ANTIBODY (mAb) - Google Patents

ESTABLISHMENT METHOD OF CELL LINE FOR PREPARING ANTI-EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) FULLY-HUMANIZED MONOCLONAL ANTIBODY (mAb) Download PDF

Info

Publication number
AU2019422095A1
AU2019422095A1 AU2019422095A AU2019422095A AU2019422095A1 AU 2019422095 A1 AU2019422095 A1 AU 2019422095A1 AU 2019422095 A AU2019422095 A AU 2019422095A AU 2019422095 A AU2019422095 A AU 2019422095A AU 2019422095 A1 AU2019422095 A1 AU 2019422095A1
Authority
AU
Australia
Prior art keywords
cell
cells
cell line
concentration
medium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2019422095A
Other languages
English (en)
Inventor
Changjiang DENG
Mingli LI
Mingxuan LI
Chuandong NIU
Jinhua XING
Chunguang YIN
Xiaomeng Zhou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shandong Inomic Institute Of Pharmaceutical Research Co Ltd
Jining University
Original Assignee
Shandong Inomic Institute Of Pharmaceutical Research Co Ltd
Jining University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shandong Inomic Institute Of Pharmaceutical Research Co Ltd, Jining University filed Critical Shandong Inomic Institute Of Pharmaceutical Research Co Ltd
Publication of AU2019422095A1 publication Critical patent/AU2019422095A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2019422095A 2019-01-15 2019-07-30 ESTABLISHMENT METHOD OF CELL LINE FOR PREPARING ANTI-EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) FULLY-HUMANIZED MONOCLONAL ANTIBODY (mAb) Pending AU2019422095A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201910035505.4 2019-01-15
CN201910035505.4A CN109988751A (zh) 2019-01-15 2019-01-15 一种用于制备抗egfr全人源化单克隆抗体的细胞株构建方法
PCT/CN2019/098387 WO2020147298A1 (zh) 2019-01-15 2019-07-30 一种用于制备抗egfr全人源化单克隆抗体的细胞株构建方法

Publications (1)

Publication Number Publication Date
AU2019422095A1 true AU2019422095A1 (en) 2021-08-12

Family

ID=67129173

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2019422095A Pending AU2019422095A1 (en) 2019-01-15 2019-07-30 ESTABLISHMENT METHOD OF CELL LINE FOR PREPARING ANTI-EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) FULLY-HUMANIZED MONOCLONAL ANTIBODY (mAb)
AU2019101814A Active AU2019101814A4 (en) 2019-01-15 2019-07-30 ESTABLISHMENT METHOD OF CELL LINE FOR PREPARING ANTI-EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) FULLY-HUMANIZED MONOCLONAL ANTIBODY (mAb)

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2019101814A Active AU2019101814A4 (en) 2019-01-15 2019-07-30 ESTABLISHMENT METHOD OF CELL LINE FOR PREPARING ANTI-EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) FULLY-HUMANIZED MONOCLONAL ANTIBODY (mAb)

Country Status (3)

Country Link
CN (1) CN109988751A (zh)
AU (2) AU2019422095A1 (zh)
WO (1) WO2020147298A1 (zh)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110016080A (zh) * 2019-01-15 2019-07-16 济宁学院 一种抗egfr全人源化单克隆抗体的纯化工艺
CN109988751A (zh) * 2019-01-15 2019-07-09 济宁学院 一种用于制备抗egfr全人源化单克隆抗体的细胞株构建方法
CN114457004B (zh) * 2021-12-23 2024-04-16 江苏为真生物医药技术股份有限公司 生物样品中外泌体分离方法、试剂盒及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100494370C (zh) * 2006-05-26 2009-06-03 神州细胞工程有限公司 一种优化的单克隆抗体
NZ581316A (en) * 2007-05-25 2012-02-24 Symphogen As Method for manufacturing a recombinant polyclonal protein
WO2012077128A1 (en) * 2010-12-07 2012-06-14 Intas Biopharmaceuticals Limited A novel cell line development process to produce recombinant proteins using twin vector expression system
CN103898123B (zh) * 2012-12-28 2019-03-15 北京韩美药品有限公司 重组人IFN-β-1a及其生产和纯化方法
CN104894055B (zh) * 2015-06-15 2018-07-17 成都金凯生物技术有限公司 一种优化的细胞培养基、细胞培养方法及其在制备蛋白和抗体中的应用
CN106318970B (zh) * 2016-08-18 2019-06-25 广东东阳光药业有限公司 一种CHO-Dhfr表达系统细胞株的高通量筛选方法
CN107043773B (zh) * 2017-02-08 2018-09-18 四川丰讯科技发展有限公司 一种提高哺乳动物细胞中外源基因表达水平的基因片段、重组载体及其用途
CN110016080A (zh) * 2019-01-15 2019-07-16 济宁学院 一种抗egfr全人源化单克隆抗体的纯化工艺
CN109988751A (zh) * 2019-01-15 2019-07-09 济宁学院 一种用于制备抗egfr全人源化单克隆抗体的细胞株构建方法

Also Published As

Publication number Publication date
AU2019101814A4 (en) 2021-09-09
WO2020147298A1 (zh) 2020-07-23
CN109988751A (zh) 2019-07-09

Similar Documents

Publication Publication Date Title
AU2020102951A4 (en) Process for purifying fully humanized anti-egfr monoclonal antibody
AU2019101814A4 (en) ESTABLISHMENT METHOD OF CELL LINE FOR PREPARING ANTI-EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) FULLY-HUMANIZED MONOCLONAL ANTIBODY (mAb)
CN107217042B (zh) 一种生产无岩藻糖基化蛋白的基因工程细胞系及其建立方法
JP2020124204A (ja) 細胞培養物を処理する方法およびシステム
US20200377850A1 (en) Seed train processes and uses thereof
US20220145348A1 (en) Methods of culturing a mammalian cell
CN102994441A (zh) 一种细胞培养基及其制备方法和用途
KR20100017923A (ko) 재조합 폴리클로날 단백질의 제조 방법
US20220081669A1 (en) Integrated Continuous Isolation of Fluid Streams From Sterile Process Vessels
TW201936628A (zh) 無菌層析法及製法
AU2016339642B2 (en) Method for producing fusion protein having IgG Fc domain
CN103012590B (zh) 一种抗cd20单克隆抗体及其制备方法和用途
EP2655600B1 (en) Methods for culturing human myeloid leukaemia cells and cells derived therefrom
JP2015510397A (ja) 抗体凝集物レベルを低下させるためのプロセスおよびそれによって産生される抗体
CN114230669B (zh) 一种双特异性抗体的生产方法
EP2128172B1 (en) Preparation process of recombinant human p43 protein
Mukherjee et al. Mammalian Cells, Tissues and Organ Culture: Applications
WO2023235762A2 (en) Commercial-scale recombinant protein production in rat hybridoma cells

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE INVENTION TITLE TO READ ESTABLISHMENT METHOD OF CELL LINE FOR PREPARING ANTI-EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) FULLY-HUMANIZED MONOCLONAL ANTIBODY (MAB)

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: APPLICATION IS TO PROCEED UNDER THE NUMBER 2019101814